Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19

  Hideta Nakamura, Takeshi Kinjo, Wakako Arakaki, Kazuya Miyagi, Masao Tateyama, Jiro Fujita

  Critical Care ( Springer )  24 ( 1 ) 484 - 484   2020.08 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI Repository

• Late diagnosis of HIV in 2022: Why so little change?

  Collins S, Namiba A, Sparrowhawk A, Strachan S, Thompson M, Nakamura H

  HIV medicine ( HIV Medicine )  23 ( 11 ) 1118 - 1126   2022.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Background: The proportion of people who are diagnosed late is a key metric to measure the public health response to HIV. But this percentage remains stubbornly high in nearly every country. Delays in accessing antiretroviral therapy affects both (i) individual health, due to a higher risk of mortality, and (ii) population-based health, due to continued risk of transmission. Despite huge efforts to increase testing, late diagnosis continues to be an indication of a public health failure. Outline: This short review includes community perspectives on why late diagnosis continues and how it may be reduced. We discuss both structural barriers that prevent people from testing earlier and personal reasons why some people still refuse testing when offered. We note that late diagnosis is reported in all countries and in all demographic groups and that sex, gender, age, and sexuality all affect these rates. However, even in groups with high HIV awareness, such as in gay and bisexual men in the UK, more than one in three people with HIV continue to be diagnosed late. Fears and prejudice about HIV based on outdated information are still common among both health workers and people using health services. For example, testing is still not offered in primary or emergency care settings, and even free testing might not be accepted if someone fears the outcome might jeopardize their resident status, employment, relationship, or health. Summary: In addition to developing targeted projects to reach the highest-risk groups, a positive mainstream public campaign could make testing more acceptable at a broad population level across all demographics. This could challenge and repair the media campaigns from the 1980s that still contribute to the stigma that frightens people away from testing now. We hope that an effective approach in one country might also help others.

  • Access this article
    DOI
  • Search related information
    PubMed

• Mpox in people with HIV: A narrative review

  Hideta Nakamura, Kazuko Yamamoto

  HIV Medicine ( Wiley )    2024.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Objective: The 2022 global mpox outbreak disproportionately impacted people living with HIV. This review explores recent evidence on mpox in this group, focusing on clinical presentation, complications, treatment modalities and vaccine strategies. Recent findings: Recent studies have suggested that people with HIV diagnosed with mpox have a greater risk of proctitis and hospitalization compared with people without HIV. In addition, those with advanced immunosuppression face an elevated risk of severe mpox infection, which can lead to mortality. Comprehensive and prompt supportive care using antiretrovirals and mpox antivirals is crucial in this group. Although results from randomized clinical trials are still forthcoming, recent studies suggest that early initiation of tecovirimat can prevent disease progression in people with HIV. The non-replicative attenuated smallpox vaccine is well tolerated and effective in preventing monkeypox virus infections in people with HIV. Further studies are needed regarding long-term vaccine effectiveness for this population. Conclusion: Evaluating the risk of severe mpox in people living with HIV requires assessing the level of immune suppression and viral control. Universal access to vaccination is imperative to prevent the resurgence of future outbreaks.

  • Access this article
    DOI Repository

• Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study

  Uno, S; Gatanaga, H; Hayashida, T; Imahashi, M; Minami, R; Koga, M; Samukawa, S; Watanabe, D; Fujii, T; Tateyama, M; Nakamura, H; Matsushita, S; Yoshino, Y; Endo, T; Horiba, M; Taniguchi, T; Moro, H; Igari, H; Yoshida, S; Teshima, T; Nakajima, H; Nishizawa, M; Yokomaku, Y; Iwatani, Y; Hachiya, A; Kato, S; Hasegawa, N; Yoshimura, K; Sugiura, W; Kikuchi, T

  JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY ( Journal of Antimicrobial Chemotherapy )  78 ( 12 ) 2859 - 2868   2023.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Neurocognitive impairment, and anxiety symptoms may influence the development of prefrailty/frailty in Japanese people living with HIV aged over 40 years

  Nakamura, H; Ikemiyagi, N; Arakaki, W; Yamamoto, K

  HIV MEDICINE   24   56 - 56   2023.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2024.04  -